Z. Wasserman

发表

Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships

Chen Lihua, Zelda R. Wasserman, Karl D. Hardman, 2002 .

Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.

David J Nelson, D. J. Nelson, Zelda R Wasserman, 2003, Chemistry & biology.

Protein design, a minimalist approach.

W. DeGrado, J. Lear, Z. Wasserman, 1989, Science.

Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics*

Michael Bower, Richard Wynn, Ronald Klabe, 2006, Journal of Biological Chemistry.

Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics.

Zelda R. Wasserman, Paul J. Ala, Ronald M. Klabe, 2006 .

A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.

Andrew Tebben, Zelda R Wasserman, A. Tebben, 2007, Bioorganic & medicinal chemistry letters.

Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

R. Magolda, J. Trzăskos, M. Covington, 2003, Bioorganic & medicinal chemistry letters.

Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.

M. Covington, C. Decicco, J. Duan, 2005, Bioorganic & medicinal chemistry letters.

Identification of Peptide Substrates for Human MMP-11 (Stromelysin-3) Using Phage Display*

S. P. Seitz, C. Albright, M. Kendall, 2003, Journal of Biological Chemistry.

Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.

R. Magolda, M. Covington, C. Decicco, 2001, Journal of medicinal chemistry.

Potent P1' biphenylmethyl substituted aggrecanase inhibitors.

M. Covington, C. Decicco, R. Wexler, 2002, Bioorganic & medicinal chemistry letters.

Macrocyclic amino carboxylates as selective MMP-8 inhibitors.

W. DeGrado, K. D. Hardman, R. Copeland, 1998, Journal of medicinal chemistry.

The Compton profile of urea

L. C. Snyder, T. Weber, W. Reed, 1978 .

Structural and functional-group tuning in the design of neuraminidase inhibitors.

S. Sabesan, Z. Wasserman, S. Neira, 1995, Carbohydrate research.

Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.

C. Hodge, Z. Wasserman, P. Aldrich, 1999, Journal of medicinal chemistry.

Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold.

M. Bower, R. Wynn, Phillip C. C. Liu, 2006, Bioorganic & medicinal chemistry.

Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.

D. J. Nelson, S. Mandlekar, P. Scherle, 2008, Journal of medicinal chemistry.

The molecular structure of hydrogen disulfide (H2S2) and barriers to internal rotation

J. Wendoloski, D. Dixon, D. Zeroka, 1985 .

Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production

K. D. Hardman, R. Copeland, B. Jaffee, 1999 .

Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.

R. Magolda, J. Trzăskos, M. Covington, 2003, Bioorganic & medicinal chemistry letters.

Synthetic peptides as models for ion channel proteins

W. DeGrado, J. Lear, K. Åkerfeldt, 1993 .

On the structure and stability of bipyramidal B2O3

L. C. Snyder, Z. Wasserman, 1980 .

Stability and bonding of disilyne and its isomers: A generalized valence bond‐effective potential study

L. C. Snyder, J. W. Moskowitz, Z. Wasserman, 1982 .

Molecular orbital calculation of the bond lengths and photoelectron spectrum of disilane

L. C. Snyder, Z. Wasserman, 1977 .

Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.

Zelda R Wasserman, J. Trzăskos, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

Synthetic peptides as models for ion channel proteins

Zelda R. Wasserman, William F. DeGrado, W. DeGrado, 1993 .

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

C. Hodge, Y. Wong, F. Hobbs, 1999, Journal of medicinal chemistry.

Glycine α-Ketoamides as HCV NS3 Protease Inhibitors

C. Decicco, W. Han, Z. Wasserman, 2003 .

Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors

S. Mandlekar, K. D. Hardman, R. Magolda, 2003 .

Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.

Karl Blom, Michael Bower, James Pruitt, 2005, Journal of medicinal chemistry.

Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.

B. Jaffee, R. Magolda, J. Trzăskos, 2001, Journal of Medicinal Chemistry.

Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.

P. Domaille, M. Bukhtiyarova, N. Farrow, 2002, Chemistry & biology.

Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.

M. Bower, R. Wynn, Wenyu Zhu, 2006, Journal of medicinal chemistry.

Synthetic amphiphilic peptide models for protein ion channels.

W. DeGrado, J. Lear, Z. Wasserman, 1988, Science.

Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.

S. Mandlekar, K. D. Hardman, R. Magolda, 2003, Journal of medicinal chemistry.

Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

C. Decicco, Z. Wasserman, Carl P Decicco, 2003, Bioorganic & medicinal chemistry letters.

Molecular orbital theory of the electronic structure of organic compounds. 28. Geometries and energies of singlet and triplet states of the C3H2 hydrocarbons

L. Radom, J. Pople, W. Hehre, 1976 .

Sequence and structural homologies among type I and type II interferons

W. DeGrado, V. Chowdhry, Z. Wasserman, 1982, Nature.

Sultam hydroxamates as novel matrix metalloproteinase inhibitors.

K. D. Hardman, J. Trzăskos, M. Covington, 2004, Journal of medicinal chemistry.

Structure of the disilene ground state: singlet silylsilylene

L. C. Snyder, Z. Wasserman, 1979 .

Use of Synthetic Peptides for the Study of Membrane Protein Structure

W. DeGrado, J. Lear, Z. Wasserman, 1994 .

Making a new turn in matrix metalloprotease inhibition.

Z. Wasserman, 2005, Chemistry & biology.

Fitting an inhibitor into the active site of thermolysin: A molecular dynamics case study

C. Hodge, C N Hodge, Z. Wasserman, 1996, Proteins.

A molecular mechanics/grid method for evaluation of ligand–receptor interactions

Pieter F. W. Stouten, James Andrew McCammon, Martin Zacharias, 1995, J. Comput. Chem..

Molecular Recognition and Self-Organization in Fluorinated Hydrocarbons

F. Stillinger, Z. Wasserman, 1978 .

Molecular characterization of helix-loop-helix peptides.

W. DeGrado, R. Fairman, C. Altenbach, 1992, Science.

The spherical Compton profile of neopentane and the carbon–carbon single bond of diamond

L. C. Snyder, T. Weber, W. Reed, 1977 .

Molecular Structure of H2S2and Barriers to Internal Rotation

J. Wendoloski, D. Dixon, D. Zeroka, 1986 .

Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.

J. Fridman, P. Scherle, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.

M. Bower, R. Wynn, J. Fridman, 2007, Journal of medicinal chemistry.

Milk‐stool model for Si(111) surface reconstruction

L. C. Snyder, J. W. Moskowitz, Z. Wasserman, 1979 .

Computational and database retrieval approaches for determining polypeptide conformation

Francis Raymond Salemme, Z. R. Wasserman, P. C. Weber, 1991 .

Disulfide crosslinks to probe the structure and flexibility of a designed four‐helix bundle protein

L. Regan, W. DeGrado, Z. Wasserman, 1994, Protein science : a publication of the Protein Society.

Molecular SCF calculations to model (III) surface relaxation of silicon

L. C. Snyder, Z. Wasserman, 1978 .

Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.

K. D. Hardman, R. Magolda, M. Covington, 1998, Bioorganic & medicinal chemistry letters.